Amarin corporation plc

US StockHealth Care

AMRN AI Analysis Overview

Keys for Bullish View

  • Value≥4
  • Dividend≥2

Analysis Conclusion

The stock has a lower value rating; if aiming for value investing, existing long-term positions might require gradual reduction.

AMRN Current Performance

0.85%

Amarin corporation plc

0.68%

Avg of Sector

0.03%

S&P500

Top 10 High Relevance to AMRN

  • SGMT Sagimet biosciences inc
    Value -Trend 5Swing Trading 2Whale Interest 1Dividend 1
    See more

AMRN Profile

Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Price of AMRN